Revolution Medicines, Inc. (NASDAQ:RVMD) Director Sells $94,820.00 in Stock

Revolution Medicines, Inc. (NASDAQ:RVMD) Director Sushil Patel sold 2,155 shares of the stock in a transaction that occurred on Tuesday, July 9th. The stock was sold at an average price of $44.00, for a total value of $94,820.00. Following the transaction, the director now owns 19,948 shares in the company, valued at approximately $877,712. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Revolution Medicines Trading Up 4.1 %

RVMD stock opened at $45.14 on Friday. The firm has a 50-day moving average price of $39.01 and a 200-day moving average price of $33.86. Revolution Medicines, Inc. has a 12 month low of $15.44 and a 12 month high of $45.26. The stock has a market capitalization of $7.45 billion, a P/E ratio of -12.04 and a beta of 1.44.

Revolution Medicines (NASDAQ:RVMD) last issued its earnings results on Wednesday, May 8th. The company reported ($0.70) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.05. Revolution Medicines’s revenue for the quarter was down 100.0% compared to the same quarter last year. During the same quarter last year, the business posted ($0.72) earnings per share. As a group, equities analysts predict that Revolution Medicines, Inc. will post -3.12 EPS for the current fiscal year.

Institutional Investors Weigh In On Revolution Medicines

Hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. grew its holdings in shares of Revolution Medicines by 51.8% during the fourth quarter. Vanguard Group Inc. now owns 14,634,391 shares of the company’s stock worth $419,714,000 after purchasing an additional 4,990,800 shares during the last quarter. Wellington Management Group LLP grew its holdings in Revolution Medicines by 40.8% during the 4th quarter. Wellington Management Group LLP now owns 14,882,086 shares of the company’s stock worth $426,818,000 after acquiring an additional 4,309,611 shares during the last quarter. Baker BROS. Advisors LP increased its position in Revolution Medicines by 46.6% in the 1st quarter. Baker BROS. Advisors LP now owns 7,549,249 shares of the company’s stock valued at $243,312,000 after acquiring an additional 2,400,592 shares during the period. BVF Inc. IL raised its stake in shares of Revolution Medicines by 50.2% during the fourth quarter. BVF Inc. IL now owns 5,981,212 shares of the company’s stock valued at $171,541,000 after acquiring an additional 2,000,000 shares during the last quarter. Finally, Janus Henderson Group PLC lifted its holdings in shares of Revolution Medicines by 77.9% during the first quarter. Janus Henderson Group PLC now owns 3,912,119 shares of the company’s stock worth $126,067,000 after purchasing an additional 1,712,639 shares during the period. Institutional investors own 94.34% of the company’s stock.

Analyst Ratings Changes

Several research firms have weighed in on RVMD. Wedbush increased their price objective on Revolution Medicines from $42.00 to $46.00 and gave the stock an “outperform” rating in a research report on Thursday, May 9th. Barclays assumed coverage on shares of Revolution Medicines in a research note on Friday. They issued an “overweight” rating and a $52.00 price objective for the company. Needham & Company LLC restated a “buy” rating and set a $46.00 target price on shares of Revolution Medicines in a research report on Thursday, May 9th. Oppenheimer lifted their price target on shares of Revolution Medicines from $43.00 to $45.00 and gave the company an “outperform” rating in a research report on Friday, April 12th. Finally, Jefferies Financial Group began coverage on Revolution Medicines in a research note on Monday, July 8th. They set a “buy” rating and a $63.00 price objective on the stock. Eleven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $45.58.

About Revolution Medicines

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.